1. Introduction
Visceral leishmaniasis, also known as “kala-azar”, is an infectious, non-contagious disease caused by leishmanine protozoan parasites of the order Kinetoplastea, family Trypanosomatidae, and genus
Leishmania Ross 1903. These have all been grouped together into the
Leishmania (
Leishmania)
donovani complex, which comprises of three valid species:
Leishmania (
L.)
donovani Laveran & Mesnil 1903 (Africa/India),
Leishmania (
L.)
infantum Nicolle 1908 (Europe/North Africa), and
Leishmania (
L.)
chagasi Lainson & Shaw 1987 (=
Leishmania chagasi Cunha & Chagas 1937) (Central and South America) [
1,
2,
3,
4,
5,
6].
In Latin America, the disease is known as American visceral leishmaniasis (AVL) or even as “neotropical calazar”, and its main vector is the phlebotomine species
Lutzomyia longipalpis (Psychodidae: Phlebotominae) [
1,
7]. AVL mainly affects children ages one to ten years-old, however, it can also affect young adults, with males being the most involved. The clinical features of the disease may appear gradually or suddenly, and it usually begins with a daily fever that lasts for up to two months, generalized body weakness, indisposition, loss of appetite, weight loss, mucocutaneous pallor, and abdominal distension that occurs due to the progressive enlargement of the liver and spleen (hepatosplenomegaly). This hepatosplenomegaly occurs as a result of hyperplasia and hypertrophy of the mononuclear phagocytic system (SFM) in the parenchyma of these viscera. In the absence of proper diagnosis and treatment, this condition almost always leads to death. Pancytopenia (anemia, leukopenia, and thrombocytopenia) and suppression of T-cell immune response (mainly CD4/Th1 cells) are significant immunopathological disorders that are responsible for intercurrences such as bronchopulmonary and intestinal infections. When these intercurrences occur with hemorrhages that result from uncontrolled coagulation, they account for the deaths that occur in the advanced stages of the disease [
8,
9,
10].
Although AVL can be considered to be the main clinical-immunological manifestation that results from interactions between the parasite and human immune system from a medical and/or public health point of view [
11], it is worth noting that in some Central American countries such as Honduras, El Salvador, Nicaragua and Costa Rica, the infection may also present atypically in teenagers and young adults. This atypical picture may only compromise the skin (with no evidence of visceral involvement), where non-ulcerated lesions with a papular and/or nodular appearance may be seen disseminated on the face, pinnae, thorax, back, and upper and lower limbs evolving over months or even years. This was initially described as a new variant of cutaneous leishmaniasis from the infection due to “Leishmania donovani chagasi” by the pioneering work of Professor Ponce’s research group in the Amapala municipality on the west coast of Honduras (El Tigre Island) [
12,
13].
Almost simultaneously, this new clinical variant of cutaneous leishmaniasis, currently recognized as non-ulcerated cutaneous leishmaniasis (NUCL) or atypical dermal leishmaniasis (ADL), was also described in Costa Rica [
14]; however, it was associated with another leishmanine parasite, “
Leishmania infantum”, which led these authors to consider that the parasite had been introduced from Europe to the New World. It is interesting to note, however, that a few years later, a genotypical analysis using the kDNA RFLP and RAPD techniques to identify the causal agent of both clinical forms (NUCL and AVL) in Honduras confirmed that
L. (
L.)
chagasi was the causal agent of both forms of the disease [
15].
It is therefore necessary to point out that the clinical picture referred to as NUCL or ADL comprises of a clinical entity that is exclusively characterized by cutaneous manifestations (with no previous history of AVL) that are mainly represented by closed lesions of a typically papular and/or nodular appearance or infiltrated plaque (without evidence of a necrotizing-ulcerative process), measuring about 5–10 mm in diameter on average. They are usually surrounded by a hypochromic halo and are commonly disseminated over the face, trunk and limbs (upper and lower), evolving over months or even years and associated, until then, to the infection by
L. (
L.)
chagasi (
Figure 1) [
12,
13,
15]. This clinical picture clearly differs from that of AVL, although in some occasions AVL patients may simultaneously present with skin lesions (sometimes even with an ulcerative character) that seem to represent a dermal manifestation of the systemic infection by
L. (
L.)
chagasi [
16,
17].
Another condition worth mentioning here refers to what was considered the first case of “active cutaneous leishmaniasis” caused by
Leishmania donovani chagasi in the New World [
18]. This case was seen in a 35-year-old female patient residing in the municipality of Rio de Janeiro, Rio de Janeiro State, Brazil and presented as a typical ulcerated skin lesion (3 cm in diameter) on the left lower limb with almost three months of evolution. This clearly differs from the clinical picture referred to as NUCL or the variant of cutaneous leishmaniasis described by Ponce et al. [
12,
13]. More recently, another similar rare case caused by
Leishmania (
L.)
infantum chagasi was diagnosed as “American cutaneous leishmaniasis (ACL)”. This case showed three ulcerated skin lesions (also morphologically different from those with a papular and/or nodular aspect or infiltrated plaque typical of NUCL) on the face of an elderly patient (over eighty-years-old) that had been evolving for about seven months. The patient was also from the municipality of Rio de Janeiro, Rio de Janeiro State, Brazil, where there was no previous record of ACL by
Leishmania (
V.)
braziliensis [
19].
Based on the comments above, a diagnostic approach in the original area (El Tigre Island, Amapala municipality, west coast of Honduras) that Ponce et al. [
12,
13] carried out their pioneering study on the variant of cutaneous leishmaniasis (today, NUCL) caused by
L. (
L.)
chagasi [
15] was recently began (2017). This approach sought to better understand the biological and molecular (genomic) characteristics of the Honduran leishmanine parasite, as well as the epidemiological aspects of human (and also canine) infection and its physiopathogenic (or immunopathogenic) mechanisms responsible for the largest clinical-immunological spectrum of that infection in Latin America [
20]. The evidence gathered so far (which is the reason for the publication of this manuscript), based on taxonomic characters of a biological [
21,
22], epidemiological [
23,
24], clinical-immunological [
20,
25,
26,
27,
28,
29,
30,
31] and molecular (genomic/phylogenetic) [4,5 Figueroa et al. unpublished data; Vasconcelos dos Santos et al. unpublished data] nature related to this leishmanine parasite, point to the characterization of a new leishmanine species,
Leishmania (
Leishmania)
poncei n. sp. [Kinetoplastea: Trypanosomatidae] (
Figure 2A,B), in honor of Professor Carlos Ponce, who was the first researcher to describe NUCL in Honduras, Central America.
3. Discussion
This represents a unique integrative taxonomic analysis of the biological, epidemiological, clinical-immunological and molecular (genomic/phylogenetic) characters of the Honduran leishmanine parasite responsible for both clinical forms of leishmaniases (NUCL and AVL) in Honduras, Central America. This is quite different from other studies that have recently described new
Leishmania species of the subgenus
L. (
Mundinia) Shaw, Camargo and Teixeira 2016, such as,
Leishmania (
Leishmania)
martiniquensis [=
Leishmania (
Mundinia)
martiniquensis emend: Shaw, Camargo and Teixeira 2016],
Leishmania (
Mundinia)
orientalis,
Leishmania (
Mundinia)
chancei and
Leishmania (Mundinia)
procaviensis [
53,
54,
55,
56], i.e., all representatives of a new taxonomic status within a subgenus that was recently described and, therefore, generating new taxonomic expectations. In contrast, the last valid species of the subgenus
L. (
Leishmania) that was described was
Leishmania (
L.)
waltoni Shaw, Pratrong, Floeter-Winter, et al. 2015, a new causal agent of anergic diffuse cutaneous leishmaniasis (ADCL) in the Dominican Republic (Central America) after almost three decades following the first parasite isolates [
57]. It does not seem like a very difficult task to understand the meaning of the present work, since more than three decades after the original description of NUCL in Honduras, Central America [
12], the question that is still heard is whether this atypical clinical form of cutaneous leishmaniasis has the same causal agent as the visceral form of the disease (AVL). This implies that NUCL is just a clinical manifestation arising from man’s resistant immune response to this infection or that its etiological agent really has a specific taxonomic characteristic that not only differentiates it from the AVL agent (
L. (
L.)
chagasi) currently recognized in Latin America, but also that it could be clinically translated by the atypical dermatological manifestation of the infection known as NUCL. As mentioned here, since the work of Noyes et al. [
15] that addressed this issue by comparing some parasite strains isolated from the cutaneous (NUCL) and visceral (AVL) forms using molecular techniques (kDNA RFLP and RAPD), there has already been an almost conclusive answer suggesting that the etiological agent was the same in both forms of the disease. Therefore, the most reasonable answer is that NUCL seems to be the main clinical manifestation arising from man’s resistant immune response to the infection, as NUCL represents the most prevalent clinical form of the infection in Honduras [
20].
It is important to make it clear that NUCL is a clinical condition that is frequently seen in the studied area (El Tigre Island, Amapala municipality, west coast of Honduras) and other Central American countries such as El Salvador, Nicaragua, and Costa Rica, rather than a sporadic clinical condition such as the ulcerative cutaneous leishmaniasis (~ACL) that is caused by
L. (
L.)
chagasi in Brazil, which has only been reported on a few occasions [
18,
19,
58]. Although there is previous evidence that suggests that the causal agent of NUCL and AVL is the same (i.e., both clinical forms had
L. (
L.)
chagasi as the causal agent) [
15], it is difficult to explain that the same causal agent is capable of inducing such diverse clinical conditions, i.e., the frequent NUCL seen in Central America and the sporadic ulcerative cutaneous leishmaniasis (~ACL) in South America. The different clinical characteristics of these two clinical conditions; on one hand, NUCL in Central America with clearly closed skin lesions of papular and/or nodular appearances or infiltrated plaques, and the ulcerative cutaneous leishmaniasis in South America on the other hand, seems to strongly signal that the etiologic agents involved (i.e., the one mainly responsible for NUCL and, less often, for AVL in Central America, and the other mainly responsible for AVL and, rarely, for ulcerative cutaneous leishmaniasis in South America) are, in fact, distinct parasitological entities with specific taxonomic characters, i.e.,
Leishmania (
Leishmania)
poncei, a new
Leishmania sp. in honor of Professor Ponce, who was the first researcher to describe the atypical NUCL in Honduras, and
Leishmania (
L.)
chagasi Lainson & Shaw 1987 (=
Leishmania chagasi Cunha & Chagas 1937) mainly responsible for AVL and, less often, for ulcerative cutaneous leishmaniasis in Brazil (South America). This is shown by the integrative, taxonomic analysis of the biological, epidemiological, clinical-immunological, and molecular (genomic/phylogenetic) characteristics of the Honduran leishmanine parasite and confirms the specific taxonomic status of the causal agent of both clinical forms of leishmaniases (NUCL and AVL) in Honduras.
Let us consider the series of studies that took place in this integrative taxonomic analysis, starting with the analysis of the biological taxonomic character of the Honduran parasite [
L. (
L.)
poncei]. These studies revealed two findings that deserve to be highlighted; firstly, on the biochemical and functional role of the main glycoconjugate molecule on the surface of Leishmania parasite, the lipophosphoglycan (LPG). This showed, in an unprecedented way, that the LPG molecule of the parasite, unlike other Leishmania species, does not present side chains consisting of Gal (β1,4)Man(α1)-PO4 that is common to all LPGs. Furthermore, with regards to in vitro
L. (
L.)
poncei LPG interactions with macrophages from BALB/C and C57BL6 mice in view of producing nitric oxide (NO), TNF-α, and IL-6 cytokines, it was noticed that
L. (
L.)
poncei LPG was able to elicit higher levels of NO and cytokines compared to
L. (
L.)
chagasi strains that were isolated from cases of human (AVL) and canine visceral leishmaniasis (CVL) from Brazil. This was evidence that
L. (
L.)
poncei LPG has a higher ability of producing proinflammatory activity [
21].
Secondly, on the behavior of experimental
L. (
L.)
poncei infection in hamsters inoculated with strains isolated from NUCL and AVL cases of Honduras through the subcutaneous and intraperitoneal routes, it was revealed that regardless of the route of inoculation, both
L. (
L.)
poncei strains caused progressive viscerotropism and a similar parasite load in the viscera of both groups of inoculated animals (there was no observed development of skin lesions in animals inoculated subcutaneously) during the period of the experimental infection. This demonstrates that regardless of the route of inoculation,
L. (
L.)
poncei strains isolated from NUCL and AVL from Honduras were capable of promoting visceral lesions in hamsters [
22]. Without a doubt, these findings represent strong evidence on the individuality of the biological taxonomic character of
L. (
L.)
poncei native to Central America, which is quite different from that of the other viscerotropic species, such as
L. (
L.)
chagasi, which originally occurs in South America. This reveals that although the viscerotropism of the Honduran parasite can be expressed in an immunologically vulnerable host, such as a hamster or young man, i.e., under five years of age, dermal tropism seems to show an advanced biological stage of evolution and/or adaptation of the parasite in the human host substantiated by the higher prevalence of symptomatic infection in the skin (NUCL) than in the viscera (AVL) [
20].
Regarding the epidemiological taxonomic character of
L. (
L.)
poncei, it is worth highlighting two other findings that reflect this issue. In this case, we are talking about the main sand fly species involved in the transmission of the parasite, as well as the behavior of canine
L. (
L.)
poncei infection in the studied area. Regarding the sand fly species,
Lutzomyia longipalpis (81%) and
Pintomyia evansi (16%) have been previously identified as the most prevalent species [
39,
40], with
L. (
L.)
poncei infection rates of 9.4% and 2.7% detected by PCR respectively [
23]. It is still too early to say what these findings represent even in terms of the vector capacity of these sand fly species for transmitting
L. (
L.)
poncei. Considering previous records of the natural infection of these sand fly species by the closest Leishmania species, i.e.,
L. (
L.)
chagasi [
41,
42,
43]
, it seems likely that
Lutzomyia longipalpis and
Pintomyia evansi play an important role in the transmission of
L. (
L.)
poncei infection, which also represents the first record of this finding in Honduras, Central America.
Another epidemiological parameter that was used as a comparison between these two closely related parasitological entities, i.e.,
L. (
L.)
chagasi versus
L. (
L.)
poncei, was the behavior of canine infection in the endemic area. As already well documented, canine
L. (
L.)
chagasi infection (CVL) in AVL endemic areas in South America, using Brazil as a reference area, has systematically revealed that the domestic dog is highly susceptible to this infection, evolving with a high parasitic load on the skin, regardless of its clinical status (symptomatic or not), which gives it the status of domestic CVL reservoir, in addition to presenting a high mortality rate from the disease [
44,
45,
46,
47,
48,
59]. However, unlike what has been previously recorded in CVL by
L. (
L.)
chagasi in Latin America, mainly in AVL endemic areas in Brazil (South America), canine
L. (
L.)
poncei infection in the endemic area of NUCL in the present study has, from a clinical point of view, proven to be almost absolutely unnoticed such that there were no dogs with typical signs or reported cases of dog deaths from suspected CVL cases before the diagnostic approach of the canine infection in that area was carried out. It was possible to detect some clinical signs of canine infection such as weight loss (64%), alopecia (7%), onychogryphosis (5%), and skin lesions (1%) after requesting specialized veterinary professional support. Thus, although we have confirmed by immunological (seroprevalence of canine infection with DDP
® quick test and/or in-house ELISA was 41%) and molecular (positive PCR in 94% of the dogs but with a very low parasite load in the buffy coat) parameters, the presence of canine
L. (
L.)
poncei infection (but without histological evidence of the parasite and of an inflammatory process in the skin lesions) denotes that the pathogenesis of canine
L. (
L.)
poncei infection is undoubtedly much less severe than that caused by
L. (
L.)
chagasi in South America, mainly in Brazil. There is also a lower parasite load at the site of infection, mainly in the skin, which shows that there is a lower risk of dogs serving as a source of infection for the sand fly species that are potential vectors (
Lutzomyia longipalpis and
Pintomyia evansi) of the parasite in the NUCL endemic area of Honduras, Central America [
24].
Therefore, although we have emphasized the epidemiological taxonomic character of canine
L. (
L.)
poncei infection, it can also be seen that there is a crossing of this aspect with the pathogenesis of canine infection, which clinically reveals marked differences between canine infections by these two taxonomically distinct parasites, i.e.,
L. (
L.)
poncei and
L. (
L.)
chagasi. Due to the clinical characteristics of canine and of human infections, it is possible to observe that
L. (
L.)
poncei is capable of causing a clinical condition (NUCL) that can be recognized as closed skin lesions of the papular and/or nodular types or infiltrated plaques. Conversely,
L. (
L.)
chagasi induces a clearly ulcerated skin lesion that has been compared to the picture of American cutaneous leishmaniasis (ACL). In line of these differences in the clinical character of infection between
L. (
L.)
poncei and
L. (
L.)
chagasi, it is worth remembering that the taxonomic classification of the genus Leishmania is phylogenetically well defined and can also be described in terms of host specificity (vertebrate and/or invertebrate) and clinical parameters [
60].
In addition to the clinical characteristic of
L. (
L.)
poncei infection, we could not fail to comment on its clinical-immunological taxonomic character, as both clinical and immunological characters go together. Due to the dynamics of the infection, this diagnostic approach considered the
in situ immune response in NUCL skin lesion and the systemic humoral and cellular immune responses of the infection. It is necessary to emphasize the histopathological findings that border the inflammatory response in skin lesions that is represented by a mononuclear inflammatory infiltrate in the dermal layer ranging from mild to intense and composed mainly of lymphocytes, macrophages (with mild parasitism), and a few plasma cells, but with epithelioid granulomatous reaction in 60% of the cases studied prior to considering the in situ immune response of the main clinical manifestation of the infection. This suggests that the inflammatory response of the NUCL skin lesion (although of the closed papular and/or nodular type and, therefore, not the ulcerated type) seems to contain a significant substrate of a cellular immune nature, given the high rate (60%) of the epithelioid granulomatous reaction present in the lesion [
27]. Following this histopathological approach, several factors inherent to the immunopathological mechanisms that were expected to take part in the pathogenesis of NUCL were analyzed. This made it possible to understand that the development of NUCL is sustained by a consistent cellular immune response against the parasite. This was represented by high expressions of CD8/CD4 T-cells and Th17 cells in such a way that the parasite load within infected macrophages (mainly the M1 phenotype) was visibly low. This shows a strong association with the Th1-type protective cellular immune response that is aided by significant production of the proinflammatory cytokines IL-2, TNF-α, INF-γ, and iNOS. In contrast, this is regulated by expressions of FoxP3, IL-10, and TGF-β without compromising the success of NUCL therapy with intralesional or systemic meglumine antimoniate [
25,
26,
28,
29,
30]. Finally, although this condition does not configure a specific immune response against a particular
Leishmania species or against
L. (
L.)
poncei, it seems feasible to say that it would be in line with the suspicion of NUCL, especially when it is associated with the clinical characteristics of the disease.
Conversely, when analyzing the systemic, humoral, and cellular immune responses against
L. (
L.)
poncei infection based on a clinical, parasitological, and immunological diagnostic support, a lower (P< 0.05) expression of regulatory cytokines: IL-6, IL-10, and IL-17 was evident, with a lower (P< 0.05) expression of IgG and IgM in NUCL compared to AVL. This therefore suggests that NUCL has lower expressions of systemic, humoral and cellular immune responses compared to AVL [
31]. Furthermore, these same diagnostic parameters (clinical, parasitological, and immunological: ELISA
-IgG/IgM and DHT) made it possible to identify the broadest clinical-immunological spectrum known so far for a single
Leishmania species. This composed of three clinical-immunological profiles among the asymptomatic infected individuals [(1) Indeterminate asymptomatic infection (IAI): IgG
+/IgM
+/DTH
-, IgG
+/IgM
-/DTH
-, and IgG /IgM
+/DTH
-; (2) Resistant asymptomatic infection (RAI): IgG
+/IgM
+/DTH
+, IgG
+/IgM
-/DTH
+, and IgG
-/IgM
+/DTH
+; and (3) Final asymptomatic infection (FAI): IgG
-/IgM
-/DTH
+] and another four among the symptomatic infected ones (NUCL) [(1) Early symptomatic infection (ESI): IgM
-/IgG
-/DTH
-; (2) Indeterminate symptomatic infection (ISI): IgG
+/IgM
+/DTH
-, IgG
+/IgM
-/DTH
-, and IgG
-/IgM
+/DTH
-; (3) Resistant symptomatic infection (RSI): IgG
+/IgM
+/DTH
+, IgG
+/IgM
-/DTH
+, and IgG
-/IgM
+/DTH
+; and (4) Final symptomatic infection (FSI): IgG
-/IgM
-/DTH
+]
, which allows tracking and monitoring of the evolution of the infection in the endemic area [
21], as has been done in the Brazilian Amazon [
11,
61].
Ultimately, a genomic analysis was used to consolidate the convictions regarding the significance of differences in the clinical nature of infections between
L. (
L.)
poncei and
L. (
L.)
chagasi, as this was, in fact, the major reason for carrying out this integrative taxonomic analysis of the Honduran leishmanine parasite (Central America). Part of this analysis, especially that related to the genomics and phylogenetics of the parasite, has also confirmed the thoughts regarding the autochthonous nature of
L. (
L.)
chagasi in American territory [
1,
2,
3,
4,
5,
6] based on the simple ecological observation of the existence of primitive enzootic cycles of
L. (
L.)
chagasi in the Brazilian Amazon (South America) in wild mammals, particularly small rodents (
Proechimys sp.,
Proechimys cuvieri and
Dasyprocta sp.) or canid (
Cerdocyun thous). These animals carry the parasite inside the tropical forests in the states of Amapá (in the Wajãpi Indigenous territory, a rugged landscape covered by dense rainforest which is one of the world’s largest protected rainforests) and Pará (in an iron mining project in the Serra dos Carajás, municipality of Marabá, where the entry of domestic animals, especially dogs, is expressly prohibited). This represents irrefutable evidence of the autochthony of
L. (
L.)
chagasi on the American soil [
62,
63].
Three findings are worth mentioning here: first, it was clearly demonstrated by molecular clock comparative analysis of the DNA polymerase alpha subunit gene of the genome sequence of
L. (
L.)
poncei that was isolated from the NUCL that the Honduran parasite is significantly older (382,800 years) than
L. (
L.)
chagasi of Brazil (143,300 years),
L. (
L.)
donovani (33,776 years), and
L. (
L.)
infantum (13,000 years) [
4]. Second, structural genomic comparisons among these leishmanine parasites were also carried out and revealed that the Honduran parasite presents an unprecedented structural variation on chromosome 17 as well as the highest frequency of genomic SNPs (more than twice the number seen in the Brazilian parasite) [
5]. Third, the phylogenetic analyses: 1) based on the PCR of three mitochondrial genetic targets of the maxi circle 12S and 9S (highly conserved ribosomal) and ND7 as has also been used to reconstruct the evolutionary relationships within the Trypanosomatidae family [
64], in a sample of four isolates from the NUCL (one of which was used in the molecular clock and genomic structure analysis) revealed that the Honduran parasite represents a different lineage from that of the Brazilian parasite (
Figueroa-Fernandez et al. unpublished data) and; 2) based on DNA and RNA polymerase gene sequences that showed that
L. (
L.)
poncei is clustered in the subgenus L. (
Leishmania) complex
donovani and is also mainly diverged in the NJ-RNA Pol II tree from the
L.
infantum (European)/
L.
chagasi (South American) and
L. donovani (India) taxa (
Vasconcelos dos Santos et al. unpublished data).
Author Contributions
Conceptualization: FTS, MDL; Data curation: FTS, TVS, GVAF, CMSP, ECS, WSO, CZV, VLM, CMCG, PKR, LVL, MBC, CEPC, MDL; Funding acquisition: FTS, MDL; Investigation: FTS, TVS, GVAF, CMSP, ECS, WSO, CZV, VLM, CMCG, PKR, LVL, MBC, CEPC, MDL; Methodology: FTS, TVS, GVAF, CMSP, ECS, WSO, CZV, VLM, CMCG, PKR, LVL, MBC, CEPC, MDL; Project administration: FTS, MDL; Resources: FTS, MDL; Software: ECS, TVS; Supervision: FTS, MDL; Validation: ECS, TVS; Visualization: FTS, MDL; Writing – original draft preparation: FTS, MDL; Writing – Review & Editing: FTS, TVS, GVAF, CMSP, ECS, WSO, CZV, VLM, CMCG, PKR, LVL, MBC, CEPC, MDL. All authors read and approved the final version of the manuscript.